---
title: "Trends & Insights"
subtitle: "Key themes and future directions from R/Pharma 2025"
toc: true
---

## Executive Summary

R/Pharma 2025 marked a pivotal moment in pharmaceutical R adoption, with three dominant themes emerging: **AI/LLM integration**, **open-source transformation**, and **regulatory acceptance**. The conference showcased 16 workshops and 30+ presentations revealing an industry in rapid transition from proprietary tools to collaborative, standards-based approaches.

**Key Statistics:**
- ü§ñ **8+ sessions** on AI/LLM (50% increase from previous years)
- üìä **GSK achieved 50%+ R code** across Biostatistics
- ‚úÖ **FDA neutrality** on statistical software increasingly normalized
- üåê **CDISC ARS/ARM** driving automation and standardization

---

## 1. The AI/LLM Revolution ü§ñ

### Emergence as Dominant Theme

AI and Large Language Models were the most discussed topic, appearing in:
- **3 dedicated workshops** (ellmer basics, enterprise tooling, clinical data privacy)
- **8+ presentations** across all sessions
- **Multiple vendor tools** ({ellmer}, {llumen}, {mcpr}, Databot, {meRlin})

### From Prototype to Production

The conversation has matured from "Can we use AI?" to "How do we deploy it safely?"

**Key Developments:**

#### 1. **Enterprise-Ready Frameworks**

Organizations are building production AI systems:

- **Merck's {llumen}** - Comprehensive agentic framework used internally
  - Supports multiple LLM sources (Azure, OpenAI, local)
  - RAG with vector databases for documents
  - Database querying (SQL, Cypher, GraphQL)
  - Foundation model integration (TxGemma)
  
- **Roche's Multi-Agent Copilot** - Package-specific AI agents
  - Each internal package gets its own expert agent
  - LangGraph orchestration
  - Integration with Cursor via MCP

- **A2-AI's GxP Solutions** - Validated AI workflows
  - AWS Bedrock integration
  - MCP server implementations
  - Compliance documentation

#### 2. **Privacy-Preserving Approaches**

Critical for pharma with sensitive clinical data:

- **On-premise LLM deployments** (llama.cpp)
- **Query sanitization** removing PII
- **Audit logging** for compliance
- **Role-based access** controls
- **{DataChat} example** - Chat interface with data never leaving secure environment

#### 3. **Practical Applications**

Moving beyond novelty to genuine productivity:

**Data Exploration:**
- Natural language queries on CDISC data
- Conversational interfaces for non-programmers
- RAG-powered document search

**Code Assistance:**
- Context-aware programming help
- Debugging complex statistical code
- Documentation generation

**Report Automation:**
- LLM-powered table summarization
- Narrative generation from results
- QC log generation

### Standards Emerging

**Model Context Protocol (MCP):**
- Standardized interface for AI tools
- R implementation via {mcpr}
- Cross-language interoperability
- Growing ecosystem (Claude Code, Cursor, VS Code)

### Challenges Identified

Despite enthusiasm, several barriers remain:

- ‚ö†Ô∏è **Validation complexity** - How to validate non-deterministic outputs
- ‚ö†Ô∏è **Cost management** - API costs at scale
- ‚ö†Ô∏è **Regulatory uncertainty** - Limited guidance on AI in submissions
- ‚ö†Ô∏è **Skills gap** - Prompt engineering and AI orchestration expertise

---

## 2. Open-Source Transformation üåê

### GSK's Landmark Achievement

**Sam Warden's** presentation on GSK's journey was a conference highlight:

**Timeline:**
- **2018-2020:** Pilot programs and early adopters
- **2020-2022:** COVID acceleration and platform adoption
- **2023-2024:** 50%+ R code target **achieved**
- **2025:** Rburst initiative for full integration

**Success Factors:**
1. **Executive commitment** - Clear target setting (50%+ R)
2. **Multi-wave approach** - Gradual transformation
3. **Training investment** - Bookdown courses, Resource Hub, AccelerateR
4. **Platform deployment** - Posit Workbench for infrastructure
5. **Cultural change** - Growth mindset and adaptability

### Industry-Wide Movement

GSK is not alone - the tipping point has been reached:

**Novartis:**
- Mosaic platform for ARS-driven TFL automation
- Standards-based, language-agnostic approach
- React UI with R backend

**Roche/Genentech:**
- Leading {admiral}, {teal}, {gtsummary} development
- autoslideR for slide automation
- {crane} for pharma-specific reporting

**Pfizer:**
- Custom R packages for RWD programming
- Dual R/SAS syntax support
- Quarto documentation sites

**Moderna:**
- AI-enhanced Shiny apps for trial data
- ellmer/GPT integration
- Accelerating exploratory analysis

### Pharmaverse Ecosystem

The collaborative open-source movement is thriving:

**Key Packages:**
- **{admiral}** - Transitioning to stable maintenance (feature complete)
- **{teal}** - Version 1.0 released (interactive apps)
- **{gtsummary}/{crane}** - Clinical table generation
- **{cardinal}** - Standardized TLG templates
- **{sdtm.oak}** - SDTM programming framework

**Benefits Realized:**
- ‚úÖ Reduced duplication across companies
- ‚úÖ Shared validation burden
- ‚úÖ Faster innovation cycles
- ‚úÖ Transparent, auditable code

---

## 3. Regulatory Evolution ‚úÖ

### FDA Software Neutrality

The 2015 FDA clarification on software neutrality is now **fully operationalized**:

- No preference for SAS vs R vs Python
- Focus on **methodology** and **validation**, not tools
- R-based submissions increasingly routine

### New FDA Guidance Impact

**2023 Covariate Adjustment Guidance** driving change:

- Novartis developed {beeca} in response
- ASA-BIOP collaboration on {RobinCar2}
- Academic methods reaching practice faster
- R enabling rapid response to guidance

### Validation Maturity

**Key Developments:**

#### 1. **Risk-Based Approaches**
- {riskmetric} for package assessment
- Shared metric repositories (R Validation Hub)
- Automated quality scoring
- Focus on critical packages

#### 2. **Acceptance-Test Driven Development (ATDD)**
- Plain-language tests in Quarto
- Shareable with regulators
- "Given-when-then" format
- Brian Repko bringing JBehave concepts to R

#### 3. **Shiny App Validation**
- Litmusverse suite (Jumping Rivers)
- Risk-based validation frameworks
- Code quality assessment
- Traceability and documentation tools

### GxP-Ready AI

Pioneering work on validating AI applications:

- **Devin Pastoor (A2-AI):** Production AI in GxP contexts
- Testing strategies for non-deterministic outputs
- Audit trails and logging
- Version control and rollback procedures

---

## 4. Automation & Efficiency üìä

### ARS/ARM as Game Changers

**CDISC Analysis Results Standard** driving automation:

**Mosaic (Novartis):**
- YAML captures ARD requirements
- Language-agnostic rules (metadata ‚Üí R or any language)
- React UI for customization
- Push-button TFL generation

**{cards} Ecosystem:**
- Analysis Results Data objects
- QC becomes straightforward (compare ARDs)
- LLMs can summarize language-agnostic results
- {crane} and {gtsummary} building on this foundation

### Report Automation

**Time Savings Achieved:**

- **autoslideR (Roche):** 0.5-4 days per slide deck
- **DMC materials automation:** Week ‚Üí Day for exposure reports (AstraZeneca)
- **LLM-powered {gtsummary}:** Submission-ready tables in minutes vs hours

**Technologies Enabling This:**

1. **officer/flextable** - Programmatic Word reports
2. **Quarto** - Multi-format publishing (PDF, HTML, presentations)
3. **Template systems** - Reusable structures (Cardinal)
4. **CI/CD pipelines** - Automated reanalysis on code changes

---

## 5. Advanced Analytics & Methods üìà

### Bayesian Methods Maturing

**Tools Reaching Production:**

- **BayesERtools** (Genentech) - Exposure-response with Stan
- **bmstate** (Generable) - Multistate survival models
- **Stan debugging workshop** - Making Bayesian accessible

**Advantages in Pharma:**
- Prior information integration
- Uncertainty quantification
- Small sample performance
- Complex model flexibility

### High-Performance Computing

**Polars for Clinical Data:**
- 10-100x faster than pandas
- Apache Arrow native
- Lazy evaluation
- Parallel processing out-of-the-box

**HPC Integration:**
- Offloading Shiny computations to clusters
- Maintaining interactive UX
- Resource optimization

### Machine Learning

**TabPFN** - Novel deep learning for tabular data:
- No training required (pre-trained on priors)
- Fast inference
- Bayesian-like uncertainty
- Promising for exploratory analysis

**Synthetic Data:**
- {synthpop} for privacy-preserving data sharing
- Software testing without PHI
- Model training on synthetic patients

---

## 6. Data Quality & Validation üîç

### {pointblank} Adoption

Comprehensive data validation framework:

**Use Cases:**
- Quick dataset understanding (`scan_data()`)
- Validation at scale (35+ tables daily)
- Beautiful automated documentation
- Integration with databases, Arrow, Shiny

**Pharmaceutical Applications:**
- SDTM compliance checks
- ADaM dataset verification
- Cross-domain consistency
- Longitudinal data integrity

### Automated Traceability

**DevOps Principles in Pharma:**

Graticule's approach:
- Docker containers for reproducibility
- CI/CD for automatic reanalysis
- Version control with validated outputs
- Cloud storage (AWS S3) for results

**Benefits:**
- Clear audit trail
- Reproducible analyses
- Automated documentation
- Integrated QC

---

## 7. Specialized Applications üß¨

### Real-World Evidence

**Pfizer's RWD Programming:**
- Custom R package for database queries
- Dual R/SAS syntax support
- Shiny apps for workflow support
- Quarto documentation

### Niche Medical Devices

**Abbott's Synthetic Data:**
- {synthpop} for diagnostics
- Privacy-preserving test data
- Validation datasets

### Oncology Innovations

**PMDA Inquiries:**
- {cards} for rapid response (Japan regulatory)
- Structured ARD approach
- Accelerated turnaround

### Pharmacokinetics

**aNCA (Pharmaverse):**
- Open-source NCA software
- PKNCA backend (200+ parameters)
- 100% test coverage
- Validated against commercial tools (¬±0.1%)

---

## 8. Regional Insights üåè

### Asia/Pacific Innovations

**Strengths:**
- Strong PMDA regulatory focus
- Practical automation tools
- Under-represented population research
- Genetic diversity considerations

**Notable Presentations:**
- SHIONOGI's open-source culture
- {meRlin} AI assistant
- PMDA e-CRT automation
- Vibe Coding approaches

### Global Collaboration

Conference demonstrated truly global R pharma community:
- Workshops from US, Europe, Asia
- Shared challenges and solutions
- Pharmaverse as unifying force

---

## 9. Future Directions üîÆ

### Short-Term (2025-2026)

**AI Integration:**
- ‚úÖ More validated AI applications in production
- ‚úÖ MCP ecosystem expansion
- ‚úÖ Regulatory guidance on AI in submissions
- ‚úÖ Cost-effective on-premise LLM solutions

**Automation:**
- ‚úÖ ARS/ARM adoption across industry
- ‚úÖ Push-button TFL generation becomes standard
- ‚úÖ Automated slide decks and CSRs routine

**Validation:**
- ‚úÖ Shared metric repositories operational
- ‚úÖ Risk-based validation industry standard
- ‚úÖ Shiny app validation frameworks mature

### Medium-Term (2027-2028)

**Tool Consolidation:**
- Language-agnostic analysis platforms
- R/Python/Julia interoperability
- Cloud-native pharma analytics

**Regulatory:**
- AI-specific guidance documents
- Electronic submissions with code
- Real-time regulatory review platforms

**Skills:**
- AI/LLM literacy standard for programmers
- Bayesian methods more accessible
- DevOps practices ubiquitous

### Long-Term (2029+)

**Transformative Possibilities:**

1. **AI-Designed Clinical Trials**
   - LLMs suggesting optimal designs
   - Automated SAP generation
   - Real-time adaptation

2. **Fully Automated TFLs**
   - From data lock to submission package
   - Human review only, no coding
   - Multi-language outputs for global submissions

3. **Real-Time Safety Monitoring**
   - Continuous analysis during trials
   - AI-detected signals
   - Predictive adverse event modeling

4. **Personalized Trial Design**
   - Bayesian adaptive with real-time learning
   - Biomarker-driven enrollment
   - Precision medicine integration

---

## 10. Challenges & Barriers ‚ö†Ô∏è

### Technical Challenges

**Validation Complexity:**
- Non-deterministic AI outputs
- Rapidly evolving tools
- Keeping pace with innovation

**Integration Issues:**
- Legacy system compatibility
- Data silos
- IT security constraints

### Organizational Challenges

**Cultural Resistance:**
- "SAS is what we've always used"
- Fear of change
- Risk aversion in regulated environment

**Resource Constraints:**
- Training investment required
- Dual maintenance (SAS + R) during transition
- Validation documentation burden

### Regulatory Challenges

**Uncertainty:**
- Limited AI/LLM guidance
- Evolving expectations
- Regional variations (FDA vs EMA vs PMDA)

**Documentation:**
- What level of detail for AI systems?
- How to handle model updates?
- Third-party API dependencies

---

## 11. Success Patterns üéØ

### What Works

Based on successful implementations presented:

**1. Executive Sponsorship**
- Clear targets (GSK's 50%)
- Resource commitment
- Long-term vision

**2. Gradual Transformation**
- Multi-wave approach
- Pilot programs
- Learn and adapt

**3. Support Infrastructure**
- Training programs (not just one-time)
- Help desks and office hours
- Documentation and resources

**4. Community Building**
- Internal R user groups
- External pharmaverse participation
- Shared learning culture

**5. Platform Investment**
- Posit Workbench
- Version control (Git/GitHub)
- CI/CD pipelines
- Cloud infrastructure

**6. Standards Adoption**
- CDISC ARS/ARM
- Pharmaverse conventions
- Style guides and linters

---

## 12. Actionable Insights üí°

### For Organizations Starting R Adoption

1. **Start with low-risk projects** (exploratory analysis, visualizations)
2. **Invest in training** early and continuously
3. **Build internal community** (lunch & learns, Slack channels)
4. **Adopt pharmaverse packages** (don't reinvent)
5. **Establish validation framework** from day one
6. **Use Posit products** (Workbench, Connect, Package Manager)

### For Organizations Scaling R

1. **Embrace automation** (ARS/ARM, template systems)
2. **Implement CI/CD** for reproducibility
3. **Explore AI carefully** (privacy first, validate thoroughly)
4. **Contribute to pharmaverse** (share internal packages)
5. **Formalize support model** (beyond training)
6. **Plan SAS sunset** (don't maintain dual indefinitely)

### For R Professionals

1. **Learn AI/LLM basics** (will be essential skill)
2. **Master one reporting framework** (officer/flextable or Quarto)
3. **Understand validation** (not just coding)
4. **Contribute to open source** (career differentiator)
5. **Stay current** (R/Pharma, webinars, blogs)
6. **Network** (pharmaverse Slack, conferences)

---

## 13. The Bigger Picture üåç

### R/Pharma 2025 in Context

This conference revealed an industry at an **inflection point**:

**From:** 
- Proprietary, siloed tools
- Manual, repetitive coding
- Conservative, risk-averse culture
- Isolated company solutions

**To:**
- Open-source, collaborative development
- Automated, standards-driven workflows
- Innovative, evidence-based adoption
- Shared industry platforms

### Why This Matters

**For Patients:**
- Faster drug development
- More rigorous analysis
- Transparent, reproducible science
- Precision medicine enablement

**For Industry:**
- Reduced costs
- Faster time to market
- Better talent recruitment
- Competitive advantage

**For Science:**
- Reproducibility crisis addressed
- Method innovation accelerated
- Global collaboration enabled
- Democratized advanced analytics

---

## Conclusion

R/Pharma 2025 demonstrated that open-source pharmaceutical analytics is not the future‚Äî**it's the present**. With AI integration, regulatory acceptance, and enterprise adoption converging, the question is no longer "Should we adopt R?" but "How fast can we transform?"

The conference showcased:
- ‚úÖ Production-ready AI systems
- ‚úÖ Validated, GxP-compliant workflows
- ‚úÖ Major pharma success stories (GSK 50%+)
- ‚úÖ Thriving ecosystem (pharmaverse)
- ‚úÖ Regulatory confidence (FDA neutrality)

**The momentum is undeniable. The future is open source. The time is now.**

---

::: {.callout-tip}
## Stay Connected

- **R/Pharma website:** [rinpharma.com](https://rinpharma.com)
- **Pharmaverse:** [pharmaverse.org](https://pharmaverse.org)
- **Posit:** [posit.co](https://posit.co)
- **R Validation Hub:** [pharmar.org](https://www.pharmar.org)
:::

---

*Analysis compiled from R/Pharma 2025 Conference materials | Last updated: November 2025*